Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular and epidemiologic characterization of the diphtheria outbreak in Venezuela.
Strauss RA, Herrera-Leon L, Guillén AC, Castro JS, Lorenz E, Carvajal A, Hernandez E, Navas T, Vielma S, Lopez N, Lopez MG, Aurenty L, Navas V, Rosas MA, Drummond T, Martínez JG, Hernández E, Bertuglia F, Andrade O, Torres J, May J, Herrera-Leon S, Eibach D. Strauss RA, et al. Among authors: navas t. Sci Rep. 2021 Mar 18;11(1):6378. doi: 10.1038/s41598-021-85957-1. Sci Rep. 2021. PMID: 33737710 Free PMC article.
Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC. Hideshima T, et al. Among authors: navas t. Oncogene. 2024 Sep;43(40):3018. doi: 10.1038/s41388-024-03147-5. Oncogene. 2024. PMID: 39209967 No abstract available.
End-of-life care needs in cancer patients: a qualitative study of patient and family experiences.
López-Salas M, Yanes-Roldán A, Fernández A, Marín A, Martínez AI, Monroy A, Navarro JM, Pino M, Gómez R, Rodríguez S, Garrido S, Cousillas S, Navas T, Lapeña V, Fernández B. López-Salas M, et al. Among authors: navas t. BMC Palliat Care. 2024 Jun 21;23(1):157. doi: 10.1186/s12904-024-01489-1. BMC Palliat Care. 2024. PMID: 38907206 Free PMC article.
Consensus on pharmacological treatment of obesity in Latin America.
Cappelletti AM, Valenzuela Montero A, Cercato C, Duque Ossman JJ, Fletcher Vasquez PE, García García JE, Mancillas-Adame LG, Manrique HA, Ranchos Monterroso FM, Segarra P, Navas T. Cappelletti AM, et al. Among authors: navas t. Obes Rev. 2024 Apr;25(4):e13683. doi: 10.1111/obr.13683. Epub 2023 Dec 20. Obes Rev. 2024. PMID: 38123524 Review.
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Mittra A, Coyne GHOS, Zlott J, Kummar S, Meehan R, Rubinstein L, Juwara L, Wilsker D, Ji J, Miller B, Navas T, Ferry-Galow KV, Voth AR, Chang TC, Jiwani S, Parchment RE, Doroshow JH, Chen AP. Mittra A, et al. Among authors: navas t. Cancer Chemother Pharmacol. 2024 Mar;93(3):177-189. doi: 10.1007/s00280-023-04600-0. Epub 2023 Nov 27. Cancer Chemother Pharmacol. 2024. PMID: 38010394 Free PMC article. Clinical Trial.
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, Park SR, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, Chen AP. Kummar S, et al. Among authors: navas t. Invest New Drugs. 2021 Dec;39(6):1577-1586. doi: 10.1007/s10637-021-01138-x. Epub 2021 Jun 28. Invest New Drugs. 2021. PMID: 34180036 Free PMC article. Clinical Trial.
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Navas T, Kinders RJ, Lawrence SM, Ferry-Galow KV, Borgel S, Hollingshead MG, Srivastava AK, Alcoser SY, Makhlouf HR, Chuaqui R, Wilsker DF, Konaté MM, Miller SB, Voth AR, Chen L, Vilimas T, Subramanian J, Rubinstein L, Kummar S, Chen AP, Bottaro DP, Doroshow JH, Parchment RE. Navas T, et al. Cancer Res. 2020 Jan 15;80(2):304-318. doi: 10.1158/0008-5472.CAN-18-3539. Epub 2019 Nov 15. Cancer Res. 2020. PMID: 31732654 Free PMC article.
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. Navas T, et al. PLoS One. 2018 Jun 21;13(6):e0199361. doi: 10.1371/journal.pone.0199361. eCollection 2018. PLoS One. 2018. PMID: 29928062 Free PMC article.
28 results